Insider Transactions in Q4 2024 at X4 Pharmaceuticals, Inc (XFOR)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
31,897
-3.02%
|
$0
$0.56 P/Share
|
|
Oct 07
2024
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
230,645
-100.0%
|
$0
$0.55 P/Share
|
|
Oct 07
2024
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
76,920
-16.54%
|
$0
$0.56 P/Share
|
|
Oct 07
2024
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
67,695
-13.02%
|
$0
$0.57 P/Share
|
|
Oct 07
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
239,436
-18.46%
|
$0
$0.55 P/Share
|
|
Oct 07
2024
|
Mark Baldry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,127
-18.66%
|
$0
$0.58 P/Share
|
|
Oct 04
2024
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+50.0%
|
-
|
|
Oct 04
2024
|
Arthur Taveras Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+33.16%
|
-
|
|
Oct 04
2024
|
Mary Di Biase Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+30.74%
|
-
|
|
Oct 04
2024
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
532,081
+29.09%
|
-
|
|
Oct 04
2024
|
Mark Baldry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,946
+36.95%
|
-
|